Biologics have revolutionized the treatment and prevention of many disabling and life-threatening diseases.
However, biologics are contributing to the rising costs of healthcare, and this may restrict access to these important medicines.
A biosimilar is an approved biologic with comparable quality, safety and efficacy to an approved reference product.
Biosimilars can liberate healthcare resources and help more patients experience the life-enhancing benefits of biologic treatment.
Visit The Biosimilars Generation website to learn more. biosimilarsgeneration.ca
You can also consult, download and share the Biosimilar Biologics Basics visual factsheet in .PNG or .PDF.
The Biosimilars Generation website is an information resource for patients, health care providers and all Canadians about biosimilar medicines in Canada.
Easy to navigate, it offers visitors key information on the science of biosimilars in a reader friendly language, where to connect with others taking or prescribing biosimilars, what provinces are doing to make them available, and the role they play in keeping public and private drug programs affordable, today and into the future.
Sandoz, the pioneer and global leader in biosimilars
Sandoz is committed to increasing patient access to high-quality, life-enhancing biosimilars. It is the pioneer and global leader in biosimilars. In Canada, Sandoz markets six products: Omnitrope®, Erelzi®, Ziextenzo®, Riximyo®, Hyrimoz® and Inclunox®.
As a division of the Novartis Group, Sandoz is well-positioned to lead the biosimilars industry based on its experience and capabilities in development, manufacturing and commercialization.
® : Registered trademark owned or used under license by Sandoz Canada Inc.
For more on our perspective about biosimilars in Canada, please read the commentary of Karine Matteau, Vice President, Bio-Generic Hospital/Physician channel and Head Biosimilars at Sandoz Canada, during the first Global Biosimilars Week from November 16 to 20, 2020..